CCM® Therapy

Impulse Dynamics is determined to improve the lives of people with heart failure and is the developer of the innovative Optimizer® CCM® Therapy delivery system. CCM Therapy is a breakthrough heart failure treatment proven to improve quality of life for heart failure patients. CCM Therapy is specifically designed to improve systolic contraction in an effort to deliver more oxygen-rich blood to the body. CCM Therapy is a safe and effective, minimally invasive treatment option for millions of heart failure patients who otherwise have few or no effective options available to them. Optimizer® is the first and only FDA-approved device in the U.S. or elsewhere for the delivery of CCM Therapy.

Our mission at Impulse Dynamics is to exceed the expectations of patients, clinicians, and caregivers alike by developing and providing cardiac contractility modulation. The company believes in fostering innovation, transparency, and accountability in our relentless efforts to expand global access to the benefits of CCM Therapy.

www.impulsedynamics.com


 

2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Cardiac Contractility Modulation in Drug-Resistant Heart Failure

1,936 views
October 20, 2021
This video features a candid discussion between Dr. William Abraham and Prof. Andrew Coats following the recent publication of the 2021 ESC Guidelines for Heart Failure. The physicians discuss cardiac contractility modulation therapy and deliberate over appropriate timing for interventional device-based therapies for patients who remain symptomatic despite GDMT. Both doctors also share their viewpoints on patients’ quality versus quantity of life and how that balance affects their decisions and overall treatment strategies. The video also features a presentation on cardiac contractility modulation in drug-resistant heart failure given by Prof. Coats at the 2021 ESC Heart Failure Congress.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
0 Comments
Login to view comments. Click here to Login